Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents
Launched by SOLVAY PHARMACEUTICALS · Jul 14, 2006
Trial Information
Current as of May 13, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria Have a minimum total score of 16 on the JCY-BOCS, Weight is within the standard weight ± 2S.D. based on the standard weight for each age in the School Health Statistical Survey Exclusion Criteria Have the following predominant psychiatric diagnosis -Schizophrenia Have previously been treated with fluvoxamine maleate
About Solvay Pharmaceuticals
Solvay Pharmaceuticals is a global biopharmaceutical company dedicated to improving patient health through innovative research and development. As a subsidiary of Solvay, a multinational chemical and advanced materials company, Solvay Pharmaceuticals focuses on delivering transformative therapies across various therapeutic areas, including central nervous system disorders, cardiovascular health, and women's health. Committed to scientific excellence and patient-centric solutions, the company collaborates with healthcare professionals and regulatory bodies to advance clinical trials and bring safe, effective medications to market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chiba Prefecture, , Japan
Fukuoka Prefecture, , Japan
Hiroshima Prefecture, , Japan
Hokkaido Prefecture, , Japan
Hyogo Prefecture, , Japan
Hyogo Prefecture, , Japan
Kagawa Prefecture, , Japan
Kumamoto Prefecture, , Japan
Mie Prefecuture, , Japan
Nara Prefecture, , Japan
Tokushima Prefecture, , Japan
Patients applied
Trial Officials
Toshiaki Yamaguchi
Study Director
Solvay Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials